Background Robot assisted laparoscopic (RAL) surgery developed to overcome the limitations of laparoscopy to assist in surgical procedures, has high capital and operating costs. Systematically assembled evidence demonstrating its clinical and cost effectiveness would be helpful for its adoption by decision makers. Objective To summarise the evidence on the cost-effectiveness of robot-assisted laparoscopic (RAL) surgery compared with relevant alternatives. Methods and results of identified studies were assessed to identify the deficiencies in evidence and areas for further research. Methods Studies reporting both costs and outcomes for comparisons of RAL with laparoscopy and/or open surgery were systematically identified. Searches were conducted in February 2015 on MEDLINE, EMBASE and NHS EED. Quality of the included studies was assessed against a standard checklist for economic analyses. Length of hospital stay and operating time (determinants of cost), cost of intervention, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) were extracted. To aid comparison, costs were converted into a common currency and price year (2014 US dollars). Results Forty-seven eligible studies were identified (full economic evaluation n = 6 and cost analysis n = 41). Economic models were used in 11 (23 %) studies. Only three studies used a model considered representative of the disease and clinical pathway with a time-horizon allowing capture of relevant differences in outcomes across strategies. The cost of RAL varied substantially between uses, ranging from US$7011 for hysterectomy to over US$30,000 for radical cystectomy. The majority of estimates were between US$15,000 and US$25,000 per person. In part this difference is explained by the difference between studies in which costs were included. It was also identified to have higher costs than the alternatives it was compared against. Incremental cost per QALY for RAL radical prostatectomy was US$28,801-$31,763 over a 10-year period assuming 200 cases per annum. Conclusion The clinical evidence available for RAL overall and used within included studies is limited. RAL surgery costs were consistently higher than open and laparoscopic surgery. Therefore, in adopting the robotic technology decision makers need to take into account the cost effectiveness within their own systems. Economic models generated and published for radical prostatectomy and hysterectomy may be adapted to other health systems if the care pathway is similar to provide locally relevant data. 
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Introduction
Minimally invasive surgical procedures were introduced with an aim to improve clinical outcomes and patient comfort. Laparoscopic surgery, which has been used across many indications, has been advocated on the grounds that it reduces bleeding, postoperative complications and length of stay [1] . However, the open techniques that it sought to supplant have also evolved, and evidence for many conditions is that many of these proposed advantages are not as clearcut as they once were [2, 3] . Furthermore, its steep learning curve especially for complex pelvic surgical procedures such as radical prostatectomy has been a major obstacle in adoption of this approach [4] .
Robotic surgery was developed to overcome the limitations of laparoscopy to assist in surgical procedures [5] . However, it is not clear if the three-dimensional (3D) visualization and extended manual dexterity [6] (as the robot is not restricted to the range of movements possible for a surgeon unaided) improve clinical outcomes. The downsides of the equipment are a lack of tactile feedback to the surgeon and the high capital (for both the robotic equipment itself but also for the adaption of theatre space to accommodate the bulky equipment) and operating costs.
Since the introduction of the robotic-assisted laparoscopic (RAL) system in 1998 its use has spread rapidly despite there being very little systematically assembled evidence demonstrating its clinical and cost effectiveness. It is likely that there are a number of reasons for this, and marketing strategies seem play an important role [7] . Judgements on cost effectiveness of an intervention can be made on the basis of the results of an economic evaluation. An economic evaluation itself is the comparative analysis of alternative courses of action in terms of both their costs (resource use) and effectiveness (health effects) [8] . In an economic evaluation costs of a treatment are the value of the resources used to provide the treatment strategy and the resource consequences of that strategy. Benefits can be measured in either clinical terms (e.g. reduction in complications, increase in survival rates in malignancies, functional benefits) or economic measures, such as qualityadjusted life-years (QALY), which combine estimates of both quality of life (QOL) with estimates of length of life. The wider the definition of benefit used, the more likely it is to measure outcomes of importance to individuals. In a recent systematic review published in 2010, RAL was compared with contemporary laparoscopic surgery [9] . In this review all studies identified were cost analyses and there was a lack of cost-effectiveness analyses.
In this paper we seek to address one of the gaps in the current evidence base by systematically identifying and summarizing the evidence on the cost effectiveness of robotic surgical techniques in health care. We have set no limits on indication or on what might be considered a relevant comparator, although we do critically appraise these issues.
Methods
Studies in which both costs and outcomes were reported were identified as part of a systematic identification of studies comparing RAL with laparoscopy and/or open surgery. In February 2015 the following electronic databases were searched: MEDLINE, EMBASE and NHS EED. Further details of the search strategies are available in Supplementary Appendix 1.
Titles and abstracts of all studies identified by the search were assessed by one reviewer. Full texts of relevant articles then were obtained. The following inclusion criteria were applied:
• Reported in English language • Reports of full economic evaluations or cost analyses: cost analysis, cost-benefit, cost-utility, cost-minimisation and cost-effectiveness analysis Studies with no comparators, RAL groups mixed with other interventions, non-English publications, publications before January 2004 and studies basing clinical estimates on less than 50 patients per treatment arm were excluded from the review. Given the substantial developments in technology in the first few years following the initial report of RAL surgery, we opted to omit early studies and started the search from 2004 onwards.
Data were extracted by one reviewer using a pre-specified data extraction form. The quality of the included studies was assessed against a commonly used checklist for reporting economic analyses [8] . Appropriateness of the data sources for key parameters (clinical effect sizes, baseline clinical data (baseline clinical risk of events), resource use, costs, utilities) was assessed by adapting the hierarchical levels suggested by Coyle and Lee (Supplementary Appendix 2).
The length of hospital stay and operating time (determinants of cost), cost of intervention, QALY and ICER were outcomes of interest. To aid comparison, costs were converted into a common currency and price year (2014 US dollars) by first correcting for the effects of inflation using a GDP deflator index, and then converting to US dollars based on Purchasing Power Parities for GDP (http://c-cemg.org/). Finally, using the algorithm published by ISPOR Good Research Practices Task Force, an exercise of transferability of full economic assessments to other jurisdictions was used to help judge transferability of findings [10] .
Results

Summary of Search and Characteristics of Included Studies
From the searches, 388 potentially relevant abstracts and titles were identified, and after review 156 full-text articles were evaluated. From these, 47 studies were identified to be eligible and were included in the review (Fig. 1 ). Of these, full economic evaluation (i.e. cost-effectiveness, cost-minimisation, cost-utility, cost-benefit analysis) was performed in only six (13 %) [11] [12] [13] [14] [15] [16] ; the remaining articles reported cost analysis. Of note is that in many of these studies effectiveness data were also reported in the same article but these data were not interpreted along with the cost data as they would be in a full economic evaluation.
Of the 47 studies, 34 (72 %) were conducted in USA , two each in Switzerland (4 %) [51, 52] , Canada (4 %) [15, 53] , Ireland (4 %) [14, 16] and Australia (4 %) [13, 54] , and one each in Denmark (2 %) [12] , Italy (2 %) [55] , Spain (2 %) [56] , Sweden (2 %) [57] and the UK (2 %) [11] .
Two studies (4 %) considered the use of RAL in two different clinical fields (urology and gynaecology) [14, 53] . Almost half of the studies considered urological indications (n = 20; 42 %) [11-13, 15, 17, 20, 21, 24, 26, 30-35, 37, 45, 48, 54, 55, 58] ; with 14 (30 %) from obstetrics and gynaecology [16, 19, 22, 23, 28, 29, 36, 38-40, 44, 49, 56, 57] , seven (15 %)from general surgery [18, 27, 42, 43, 46, 51, 52] and three (6 %) from cardiothoracic surgery [36, 41, 47] . The annual number of new studies published started to increase in 2010, with 11 publications in 2014.
Perspective of the Studies
The majority of studies have carried out their assessments from a hospital perspective. Two (4 %) studies conducted their assessment from a societal perspective [12, 19] . A perspective from a publicly funded healthcare system was taken in five (11 %) studies [11, [14] [15] [16] 53 ].
Source of Evidence Used in the Studies
The data used as a source of evidence for the studies were summarised according to the hierarchy of Coyle and Lee (Supplementary Appendix 3). Clinical effectiveness data was gathered from multiple sources in 11 (23 %) studies [11, 14-17, 19, 20, 31, 34, 35, 53] . Of these, three studies used outcomes from meta-analysis that included both randomized controlled trials (RCTs) and non-randomised comparative studies measuring final clinical outcomes [11, 16, 53] . One (2 %) study gathered data from a prospective non-RCT single-centre study they carried out [13] and in one (2 %) study a RCT was conducted [39] . The remaining 34 (72 %) studies gathered clinical-effectiveness data from data registries. As noted above, the cost analyses also tended to report clinical outcomes but did not relate this to the cost data.
Baseline Clinical Data
The source of baseline clinical data was collected from the same jurisdiction of interest as the cost data in 38 (81 %) studies [11, 12, 16-18, 21-26, 28-30, 32, 33, 36-44, 46-52, 54-57] and from different jurisdictions in two (4 %) studies [14, 15] . For the remaining seven (15 %) studies the data came from previously published reports [13, 19, 20, 31, 34, 35, 50] .
Resource Use Data
Resource use data came from the same jurisdiction as the setting of the study in all studies except one, where expert opinion was used as the source of clinical pathway and related resource utilization [17] . Unit costs were derived from different jurisdictions in only two (4 %) studies that reviewed the literature for costs of interest [15, 53] . All the remaining studies generated costs from the jurisdiction of interest.
Utility and Benefit Assessment
Utility and benefit assessment was carried out in only five (11 %) studies [11-14, 25, 39] . Direct assessment techniques (such as SF-6D [12] , erectile and urinary continence function and pain score scale (0-10) [13] , sexual function International Index of Erectile Function Questionnaire-5 [14] ) were employed in four (8.5 %) of them [12] [13] [14] 39 ].
Quality Appraisal of the Studies
A clear description of the form of economic approach was provided in 16 (34 %) studies [11-19, 34, 39, 41, 47, 53-55] and was justified in 12 (25 %) of them [11-16, 18, 39, 41, 47, 53, 55] . In six (13 %) studies productivity effects were estimated [11, 13, 19, 23, 25, 39] and three (6 %) of them were justified as being relevant to the decision maker for which the study was conducted [11, 13, 19] . In order to provide judgements about generalisability of data it is recommended that data on resource use and costs are reported separately; this was not done in seven (15 %) studies [12, 17, 20, 22, 26, 27, 33] and was unclear in one (2 %) study [40] .
Models are used to overcome the limitations of primary studies such as RCTs [59] . However, models need to be appropriate for the questions addressed. Therefore to understand the quality of models reports should provide information on the clinical pathway and estimates used to populate the model. Moreover, the time-horizon used in the model should be representative of the clinical condition. For problems with a short time horizon decision trees are useful, while for clinical conditions with longer time frames or when probabilities vary over time state transition models are more useful [60] . In 11 (23 %) studies the evaluation used economic models [11, 14-17, 19, 20, 34, 35, 44, 51] . Seven (15 %) of these considered populations suffering from malignancies [11, 15, 17, 19, 20, 34, 44] , and 2 (4 %) others considered benign diseases (morbid obesity and ureteropelvic junction obstruction) [35, 51] . In a further two (4 %) there was a mixed group of diagnosis (benign and malign) [14, 16] . All of these diseases have clinical pathways that require follow-up, a probability of recurrence and a necessity for additional interventions, etc. Thus, a model requires having a long enough time-horizon to capture all events. In three (6 %) studies the details of the model used were not clear [34, 35, 44] . In eight (17 %) studies an attempt was made to justify the key parameters that the models were based upon [11, 14-17, 19, 44, 51] . Justification of key parameters was satisfactory in six of these [11, [14] [15] [16] [17] 44] .
In one (2 %) study that looked at prostate cancer a micro-simulation model was used and was justified since the disease has many probabilities that vary over time [11] . Two (4 %) other studies used patient cohort models on the assumption that long-term results of the interventions were similar [14, 16] . Decision tree models were used in the remaining eight studies, which are typically insufficient to adequately describe the complete disease course. In three (6 %) studies a time frame beyond the length of hospital stay extending up to 10 years was used [11, 14, 17] . This is particularly important as a longer time horizon allows benefits of a more effective but more costly intervention to accrue. The HTA report from Canada on prostate cancer comparing RAL with conventional laparoscopy and open surgery tried to justify its limitation of time horizon (length of hospitalisation) by assuming similar long-term outcomes for both treatment options [15] . However, RAL surgery probably has a slight long-term benefit in prostate cancer surgery, although a certain amount of uncertainty about this does exist [61] . In summary, in two (4 %) of the studies the models used represent the disease and clinical pathway in a well established way and time horizon that allows the capture of relevant differences in outcomes across strategies [11, 16] .
The results of an economic evaluation may be subject to a number of different uncertainties around a range of factors (including for example the uncertainty around an estimate of effectiveness in a trial). The extent to which the results of the evaluation are sensitive to plausible changes in elements of costs or effects should be explored in a sensitivity analysis [8] . However, only 16 (34 %) studies reported a detailed sensitivity analysis [11, 12, 14-16, 19, 20, 29-31, 34, 35, 37, 41, 47, 51, 53, 55] and the remaining 31 (66 %) studies omitted this element. Discounting, which is used to reflect society's or decision makers' preferences over the timing of costs and benefits, was carried out in five studies using a discount rate varying between 3.5 and 5 % [11, [14] [15] [16] 53] . It is good practice to vary the discount rates in a sensitivity analysis to understand its impact on the estimates generated.
The capital cost of the robotic system, its life span and annual number of uses of the equipment are key determinants of cost. A summary of all studies included in the review is provided in Supplementary Appendix 4. Capital costs of the robotic system were not considered in 20 (42 %) studies [18, 21-23, 26-29, 32, 33, 38, 40, 42, 43, 45-49, 54] . Since the robotic equipment will last for several years it is important to take into account the annual case number when trying to apportion the costs of that equipment to a single patient. The annual case number estimations seen for the robotic system were taken into account in almost half of the studies (n = 20; 42 %). In these studies the annual number of cases estimated ranged from 70 to 450 [11-15, 19-21, 25, 30, 31, 34, 35, 37, 39, 44, 51-53, 57] . Most studies demonstrated a sharp decline in per patient cost as the annual caseload increased. This reached a plateau at 150-200 cases per year. All studies that reported on annual caseload have also included the lifetime of the robotic system equipment in their calculations. Assumptions of equipment life varied and ranged from 5 to 10 years.
Details of the appraisal of studies according to ''Guidelines for authors and peer reviewers of economic submission to British Medical Journal'' are presented in Supplementary Appendix 5.
Costs Estimates
Cost estimates, comparator groups, annual case assumptions, LOS and geographical location of the studies are provided in Supplementary Appendix 4.
Prostatectomy
Total costs for RAL prostatectomy (range US$7504-$9737) were higher than both open prostatectomy (range US$4931-$10,567) and laparoscopy (range US$6320-$10,991) in all studies. Those studies reporting on costs only were predominantly from the USA (n = 7), and of the remaining four studies, one each was from Italy [55] , Denmark [12] , Canada [53] and Australia [54] . Three studies included the benefits and harms gained in their analysis [11, 13, 14] . In the study by Close et al. [11] from the UK, the incremental cost per QALY for RAL compared to laparoscopy over 10 years was US$28,801 for a case load of 200 cases per year. The Irish HTA found an incremental cost per QALY for RAL to be US$31,673 compared to mixed provision of laparoscopic and open prostatectomy over 10 years for a case load of 200 cases per year [14] . The Australian HTA reported an incremental cost of US$19,794 per QALY over a time horizon of 1 year [13] . RAL surgery remained costlier than other alternatives within the reported time-horizons. In the UK HTA extending the time-horizon to the patient lifetime provided a high chance of RAL surgery having an incremental cost per QALY of less than £30,000 (US$43,859), a common threshold value used in the UK [11] .
Cystectomy
Three studies, all from the USA, reported a cost analysis of RAL cystectomy with a time-horizon including only hospitalisation time in two of them [21, 30] and postoperative 90 days in one [45] . The first study published in 2009 found that RAL cystectomy (US$30,399) costs were higher than open surgery (US$26,291) [21] . This study did not include the initial purchase cost of the robotic system. The second study that included the capital cost of the equipment found that costs differed according to the type of urinary diversion [30] . RAL surgery was found to be less costly than open surgery when less complex urinary diversion types (ileal conduit in RAL cystectomy: In this study there may be an inadvertent selection bias of more frail patients being directed to open cystectomy with less complicated urinary diversion types. This can be assumed by seeing that almost all patients with clinically advanced local disease (cT3-4) were treated with open surgery (n = 13; 81 %) and fewer lymph nodes were resected in the open surgery ileal conduit group (mean number: 8) compared to the RAL surgery ileal conduit group (mean n = 16) [62] . Finally, the study lacks information about the competing risk factors (frailty, age, comorbidity status, etc.) of patients that influence the postoperative 90 days' mortality and morbidity, hence it is unclear if the comparisons made are secure from selection biases, and costs accrued from this study should be carefully interpreted as the baseline risks of the two groups are unlikely to be comparable. The final study that included 90 days' postoperative morbidity and mortality outcomes but did not include capital cost of the equipment found that RAL (US$31,007) costs were higher than open surgery (US$26,681) [45] .
Nephrectomy
Four studies, all from the USA, reported on the costs of nephrectomy for open, laparoscopy and RAL surgery) [32, 34, 37, 50] . Depending on the clinical stage of the tumour, a partial or total nephrectomy can be performed. According to the only study that reported on the total costs, nephrectomy cost of RAL (US$7504) was higher than both laparoscopy (US$6320) and open surgery (US$4931) [32] . The total cost of RAL partial nephrectomy (range US$12,786-$23,331) was higher than both laparoscopy (range US$11,021-$13,519) and open surgery (range US$12,214-$20,334) in all studies [32, 34, 37] . The time horizon of two of studies extended beyond the time patients were discharged from hospital (30 days and 6 months) [37, 50] . Two studies did not consider all important baseline parameters that could confound results [29, 31] . This is especially the case for partial nephrectomy where operation time and complications may be influenced by the anatomical complexity of the tumour [63] , and in an unbiased comparison it would therefore be important that the characteristics of the treated patients in this respect are similar. Subgroup analysis of tumour complexity using the RENAL score was done in one study [50] . The fourth study looking at partial nephrectomies had an attempt to adjust for confounders but tumour complexity was not included [37] . Additionally, effectiveness assessments were not included, i.e. positive surgical margins and health state utility values.
Pyeloplasty
The total cost of RAL pyeloplasty (range US$11,148-$12,895) was higher than both open surgery (range US$8624-$10,378) and laparoscopy (range US$9038-$9509) within the time horizon of hospitalisation [32, 35] and at 90 days postoperatively [48] . All three studies were conducted in the USA. Length of hospitalisation in RAL (1.5 [35] [48] . The main drivers of cost differences come from the equipment cost of the robotic system. Furthermore, baseline relevant factors such as previous interventions for the ureteropelvic junction obstruction were not taken into account. The possible case mix may incur a risk of bias that would influence the outcomes. Unfortunately, studies have not looked at the clinical effectiveness success rates (i.e. stricture development), quality of life or utility values, and it is not possible to draw conclusions on whether or not RAL for uteropelvic junction obstruction is cost effective or not.
Hysterectomy
Total cost of RAL hysterectomy (range US$7011-$15,399) within the time horizon of hospitalistion was higher than laparoscopy (range US$7139-$9430), open surgery (range US$6500-$13,613) and vaginal surgery (US$7464) in all studies [14, 19, 23, 28, 29, 36, 40, 53, 56, 57] other than two studies from the USA [22, 49] . One of these two studies identified RAL cost to be less than laparoscopy in patients with cervical cancer (open: US$10,280, laparoscopy: US$12,585 and RAL: US$10,877) [22] and the other identified a lower cost than abdominal surgery for benign uterine diseases (RAL vs. abdominal: -US$983 (-US$3063 to US$1099)) [49] . In a HTA report [14] and a study [16] from Ireland the long-term clinical effectiveness was assumed to be equal for all surgical approaches assessed. The incremental costs of RAL surgery compared to open/laparoscopy identified in these two studies were similar, accruing a higher cost (US$3564 [14] and US$3821 [16] ). Both of these studies used a time horizon limited to the length of hospitalisation, and this was justified by assuming similar/equal effectiveness.
Sacrocolpoplexy
Only one study, a RCT from USA, that looked at total cost of RAL sacrocolpoplexy compared to laparoscopy for patients with pelvic organ prolapse was identified [39] . In this study, the total cost of RAL sacrocolpoplexy at 6 weeks after surgery was higher (RAL: US$21,240 vs. laparoscopy: US$12,369). Similar QALYs were reported at 6 weeks after surgery between two treatment arms (RAL: 0.098 ± 0.011 vs. laparoscopy: 0.101 ± 0.009, p = 0.234). However, 1 week after surgery patients in the RAL group reported more pain (RAL: 3.5 ± 2.1 vs. laparoscopy: 2.6 ± 2.2, p = 0.044) and a higher rate of difficulty with activities that diminished 2 weeks after surgery. Additionally, 2 weeks after surgery the physical health score measured with SF-36 was also worse (RAL: 41 ± 26 vs. laparoscopy: 57.1 ± 25.6, p = 0.009). Functional outcomes measured at 6 months were similar in both groups (p [ 0.05).
Gastric Bypass Surgery
Hagen et al. [51] [51] . The time horizon in the study was length of hospitalisation. These results are representative of a centre experienced in gastric bypass surgery and would be a poor basis for population level decisions. Furthermore, the authors have postulated that complication rates in laparoscopy were influenced by a learning curve whilst this was not the case for RAL, and hence the 0 % complication rate for this surgery. However, even with the current standard practice, open surgery, the anastomosis leakage rate was reported to as 1.9 %. Hence, it may be the case that the study was underpowered to capture events (RAL case number: 143) for RAL surgery.
Myotomy and Cholecystectomy
RAL Heller myotomy total cost (US$9869) was higher on average than laparoscopic surgery (US$7441) and slightly lower than open surgery (US$10,275). This study, conducted in the USA, included the influence of post-discharge complications up to 30 days on costs [18] . The study has not presented the cost outcomes in a disaggregated form and it is not possible to exactly understand the cost data presented. However, the authors suggest that the lower costs may be due to lower complication rates of laparoscopy and RAL that may translate in to shorter hospitalisation time (see Supplementary Appendix 4). Cholescystectomy was reported to be costlier with RAL (US$8705) than with laparoscopy (US$6819) by a study reported from Switzerland [52] . The time horizon of this study was length of hospitalisation. No difference in complication rates was shown and the cost difference was attributed to the higher cost of the robotic instruments.
Antireflux Surgery
Total cost of RAL antireflux surgery ($10,966 ± 6224) was higher than both laparoscopy ($8209 ± $7180) and open surgery (US$13,152 ± 14,405) by a study reported from the USA [46] . This study included postoperative 30-day accrued hospital costs. Robot capital cost, annual case assumptions and utility measurement were not a part of this study.
Colectomy
Colectomy costs were reported in three studies that all identified RAL (range US$15,869-$20,555) to have higher total cost than laparoscopy (range US$12,790-$16,896) [27, 42, 43] . None of these studies included the robot capital cost, time-horizon beyond hospitalisation time and utility measurements. A similar approach was used in the study that reported on resection of the rectum [43] . This study has reported higher total costs for RAL surgery (US$24,531) compared with laparoscopy (US$19,269).
Coronary Artery Bypass
Cost of robotic hybrid coronary artery bypass (MiniCABG) (US$26,005) was higher than traditional open surgery (US$17,983) in the robustly performed prospectively enrolled study with a time frame of 1 year [25] . Both immediate postoperative and 1-year major complication rates were lower for MiniCABG cases (postoperative 12 % and 1-year 4 %) compared to open surgery (postoperative 37 % and 1-year 26 %). Days to return to work were also significantly shorter for MiniCABG (44.1 ± 33.1 days) compared to open surgery (93 ± 42.5 days).
Pulmonary Lobectomy
The two studies that reported on the total costs of pulmonary lobectomy identified a robotic-assisted procedure (range US$17,011-$25,798) to be higher than open (US$15,036) and video-assisted-thoracic surgery (VATS) (range US$13,289-$21,096) [41, 47] .
Transferability of Full Health Economic Studies
Transferability of full health economic studies were assessed using the algorithm published in the ISPOR guidance on this topic that consists of 4 steps [10] . These 4 steps involve establishing;
1. Is it a cost-effectiveness study? 2. Is it relevant to the decision problem and does it have a sound methodology (Table 1a) ? 3. If the study has a sound methodology see if the available report provides information on comparable treatment patterns (Table 1b ). 4. CEAs that were found appropriate to transfer should be checked to see if further adjustments are required.
All six studies that carried out a full-health economic assessment (step 1-is it a cost-effectiveness study?) [11] [12] [13] [14] [15] [16] compared RAL surgery with the relevant alternatives (step 2). A sound, comprehensive and robust methodology that was satisfactory and included a transparent health economic model was used in two of them (step 2-General knockout criteria- Table 1 [64]) [11, 16] . As noted earlier, discounting and a clear description of the perspective of the assessment were provided in both of these (Specific knockout criteria- Table 1 ). Patterns in the diseases looked at may differ according to location (step 3). Therefore, the details that will allow the local authority that wishes to transfer the assessment need to be check for applicability. The list by Welte et al. [64] may be a good source for this. However, if a decision maker from a local jurisdiction finds the treatment pathway used in the studies of Close et al. and Teljeur et al. relevant to their setting then these models can be adapted by using local costs in the models [11, 16] .
Discussion
Despite the extensive literature search we were only able to identify six (12 %) full economic evaluation studies, although 41 cost analyses were identified. All these studies varied in terms of their control of potential confounding factors and on the type of costs considered. The adopted perspective of the cost estimations is important for appropriate comparison of results amongst studies. The majority of studies (n = 40; 85 %) focused on hospital costs only and a small group adopted a publicly funded healthcare system (n = 5; 11 %). Health economic assessments are sensitive to the time-horizon that allows capture of relevant differences in outcomes across strategies. Time-horizon limited with hospital stay justification was possibly appropriate in only two studies, both of which reported on hysterectomies and carried out a cost-minimisation analysis [14, 16] . However, further studies are required to understand if this justification is appropriate as there are reports on female pelvic surgery reporting on short-term unfavourable QOL outcomes with RAL [39] . A long timehorizon would allow the capture of harm and benefits that accumulate with time. Such an approach was reported for radical prostatectomy only, with a time-horizon of 10 years. These studies identified a similar ICER per QALY (Close et al. [11] , UK: US$29,909, and Flattery et al. [14] , Ireland: US$31,463) that adopted the same perspective (publicly funded health care system) [11, 14] . Nevertheless, regardless of these differences, a higher cost was associated with RAL surgery compared to laparoscopy and/or open surgery, which is as would be expected given the higher equipment costs.
As a basis for decision making about the desirability of adopting RAL as an alternative for conventional open or laparoscopic surgeries the evidence base is insufficient. This is mostly due to lack of high-quality evidence of longterm clinical outcomes.
Based on all studies in the review only one study reported on a higher rate of unfavourable clinical outcomes with RAL surgery [39] . In this study, conducted by Anger et al., women undergoing sacrocolpopexy for pelvic organ prolapse had a higher rate of pain and discomfort after the operation compared with laparoscopy at the end of second postoperative week, but these findings should be assessed in the light of those from other studies considering different surgical interventions. The clinical benefit of RAL has only been shown in radical prostatectomies [11] and hysterectomies [14] compared to open surgery and a marginal superiority over laparoscopy. However, the clinical impact of these differences is unclear. Furthermore, there are many covariates either not included or insufficiently assessed in both the clinical effectiveness and cost-effectiveness literature, such as surgeon's learning curve, surgeon's skill, competing risk factors, frailty-fitness status, etc.
QALYs were estimated only in the HTAs from Ireland, Australia, Denmark and the UK, and only for prostate cancer patients [12] [13] [14] 61] . These studies are supportive of the use of RAL prostatectomy; however, the evidence on effectiveness they used, though systematically assembled, is still weak. Hence, there is a considerable uncertainty around its cost-effectiveness estimates. Furthermore, though the results of these studies are applicable from the perspective of their own jurisdiction, there was no attempt made to have the analysis transferred to other jurisdictions. Cost-effectiveness assessment may vary from one jurisdiction to another. Judgements about the transferability of the cost-effectiveness/minimisation analysis for radical prostatectomy and hysterectomy carried out in the UK [11] and Ireland [16] need to consider the relevance of the care pathways modeled to specific alternative settings.
It is important to be aware of the limitations of the included studies to assess the relevance of their results to present day circumstances. Firstly, only six studies attempted to combine information on costs with that on clinical outcomes [11] [12] [13] [14] [15] 25] . Secondly, evidence was assembled on clinical effect sizes, baseline clinical data, resource use, costs and utilities in only six studies [11] [12] [13] [14] [15] 25] . The limitations of the evidence base make it difficult to draw firm conclusions. The three studies that most rigorously attempted a full economic assessment (cost effectiveness and cost minimisation) looked at RAL radical prostatectomy [11, 14] and hysterectomy [16] , but as noted above we should be careful when drawing conclusions from these three studies as the evidence used to populate the model is limited [11, 14, 16] . However, the model structures generated by Close et al. [11] and Teljeur et al. [16] are representative of the clinical and disease care pathway and could be used in future studies which utilise any new evidence.
The key determinants of the cost of RAL surgery were the surgical equipment, robot purchase and maintenance, and the additional costs related to longer operative times. Further key determinants of the costs were the lifespan and number of times the equipment would be used; as the number of cases increase the incremental costs per case falls. However, the evidence is not sufficient to suggest what the optimal annual caseload would be either for a specialty in particular or across a range of specialties. For example, the Canadian HTA demonstrated that the incremental cost of RAL prostatectomy compared with open surgery ranged between US$9904 to US$207 with a corresponding annual caseload of 50 to 500 [15] . An annual caseload of 500 would require the device to be used twice a day, excluding public holidays and weekends. The plausibility of this number needs to be questioned, as the highest number of cases reported per annum was 361 across a range of diseases [30] .
Conclusion
Based on current available evidence, robotic surgical technology appears to be safe and feasible with similar clinical outcomes to open and laparoscopic surgery. However, there is uncertainty about long-term clinical outcomes as well as the effect on quality of life. Although clinical evidence of effectiveness is poor, RAL surgery costs were consistently higher than open and laparoscopic surgery. Before adopting the robotic technology, decision makers need to take into account the paucity of data on which cost-effectiveness estimates are based and the relevance of that data to their own systems. Economic models generated and published for radical prostatectomy and hysterectomy may be adapted to other health systems if the care pathway is similar to provide locally relevant data. 
